Otros idiomas Cara Therapeutics, Inc.

Acciones

CARA

US1407551092

Mercado cerrado - Nasdaq Otros sitios de cotización 22:00:00 31/05/2024			Varia. Cinco días.	Varia. 1 de enero.
0,6494 ^USD	+8,61 %		-3,25 %	-12,60 %

13/05	Cara Therapeutics, Inc. informa de los resultados del primer trimestre finalizado el 31 de marzo de 2024	CI
22/03	Cara Therapeutics, Inc. Anuncia la dimisión de la Dra. Joana Goncalves como Directora Médica, con efecto a partir del 16 de abril de 2024	CI

Otros idiomas

Desbloquee todas las noticias: ¡Sea el primero en enterarse y reaccione antes que los mercados!

Inscripción 100% Gratuita

Cara Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	13/05
Cara Therapeutics, Inc. Announces Resignation of Dr. Joana Goncalves as Chief Medical Officer, Effective April 16, 2024	22/03
CARA THERAPEUTICS, INC. : Canaccord Genuity maintient sa recommandation à l'achat	06/03
Transcript : Cara Therapeutics, Inc., Q4 2023 Earnings Call, Mar 04, 2024	04/03
Cara Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	04/03
Cara Therapeutics to Cut Workforce Up to 50%, Halt Work on Chronic Kidney Disease; Chief Scientific Officer to Exit	22/01
Transcript : Cara Therapeutics, Inc. - Special Call	22/01
Cara Therapeutics, Inc. Prioritizes Late-Stage Notalgia Paresthetica Program	22/01
Cara Therapeutics, Inc. Announces Frédérique Menzaghi Departs as Chief Scientific Officer and SVP of Research & Development, Effective February 2, 2024	22/01
CARA THERAPEUTICS, INC. : HC Wainwright toujours positif	19/12
Top Midday Decliners	18/12
CARA THERAPEUTICS, INC. : Needham & Co. reste à l'achat	18/12
Cara Therapeutics, Inc. Announces Outcome from Dose- Finding Part A of the KIND 1 Study Evaluating Oral Difelikefalin for Mod Moderate-To-Severe Pruritus in Patients with Atopic Dermatitis	18/12
CARA THERAPEUTICS, INC. : Piper Sandler n'est plus à l'achat	14/11
Cara Therapeutics Q3 Loss Widens, Revenue Drops	13/11
Transcript : Cara Therapeutics, Inc., Q3 2023 Earnings Call, Nov 13, 2023	13/11
Cara Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	13/11
CARA THERAPEUTICS, INC. : HC Wainwright maintient sa recommandation à l'achat	19/10/23
Cara Therapeutics Says Partner Receives Approval of Korsuva Injection to Treat Pruritus in Hemodialysis Patients in Japan	25/09/23
Transcript : Cara Therapeutics, Inc., Q2 2023 Earnings Call, Aug 07, 2023	07/08/23

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Cara Therapeutics, Inc.

Acciones

CARA

US1407551092

Otros idiomas

Filtros